(Reuters) – Britain’s GSK said on Wednesday its plan to split into two businesses was on track, as the drugmaker aiding in COVID-19 vaccine developments forecast 2021 profit to fall by a mid- to high-single digit percentage.
The company, which earlier in the day announced a tie-up with CureVac to develop a COVID-19 vaccine, reported a 2% fall in turnover in the three months ended Dec. 31. Adjusted earnings came in at 23.3 pence per share.
(Reporting by Pushkala Aripaka in Bengaluru and Ludwig Burger in Frankfurt; Editing by Saumyadeb Chakrabarty)
